Smith Meredith Y, Janssens Rosanne, Jimenez-Moreno A Cecilia, Cleemput Irina, Muller Mireille, Oliveri Serena, Simons Gwenda, Strammiello Valentina, Huys Isabelle, Falahee Marie
Evidera, Inc, PPD, a Part of Thermo Fisher Scientific, 6 Plainfield Street, Boston, MA, 02130, USA.
Department of Regulatory and Quality Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA.
Res Involv Engagem. 2023 Apr 7;9(1):21. doi: 10.1186/s40900-023-00430-9.
There is growing recognition of the importance of patient and public stakeholder involvement (PPI) in patient preference research. However, limited evidence exists regarding the impact, barriers and enablers of PPI in preference studies. The Innovative Medicines Initiative (IMI)-PREFER project conducted a series of preference case studies which incorporated PPI.
To describe: (1) how PPI was operationalized in the PREFER case studies, (2) the impact of PPI, and (3) factors that served to impede and facilitate PPI.
We reviewed the PREFER final study reports to determine how patient partners were involved. We conducted a thematic framework analysis to characterize the impact of PPI and then administered a questionnaire to the PREFER study leads to identify barriers and facilitators to effective PPI.
Eight PREFER case studies involved patients as research partners. Patient partners were involved in activities spanning all phases of the patient preference research process, including in study design, conduct and dissemination. However, the type and degree of patient partner involvement varied considerably. Positive impacts of PPI included improvements in the: (1) quality of the research and research process; (2) patient partner empowerment; (3) study transparency and dissemination of results; (4) research ethics, and (5) trust and respect between the research team and the patient community. Of the 13 barriers identified, the 3 most frequently reported were inadequate resources, insufficient time to fully involve patient partners, and uncertainty regarding how to operationalize the role of 'patient partner. Among the 12 facilitators identified, the two most frequently cited were (1) having a clearly stated purpose for involving patients as research partners; and (2) having multiple patient partners involved in the study.
PPI had many positive impacts on the PREFER studies. Preference study leads with prior PPI experience reported a greater number of positive impacts than those with no such experience. In light of the numerous barriers identified, multi-faceted implementation strategies should be considered to support adoption, integration and sustainment of PPI within preference research. Additional case studies of patient partner involvement in preference research are needed as well to inform best practices in this area.
患者及公众利益相关者参与(PPI)在患者偏好研究中的重要性日益受到认可。然而,关于PPI在偏好研究中的影响、障碍和促进因素的证据有限。创新药物倡议(IMI)- PREFER项目开展了一系列纳入PPI的偏好案例研究。
描述:(1)PPI在PREFER案例研究中是如何实施的;(2)PPI的影响;(3)阻碍和促进PPI的因素。
我们审查了PREFER最终研究报告,以确定患者合作伙伴是如何参与的。我们进行了主题框架分析,以描述PPI的影响,然后向PREFER研究负责人发放问卷,以确定有效PPI的障碍和促进因素。
八项PREFER案例研究让患者作为研究合作伙伴参与其中。患者合作伙伴参与了患者偏好研究过程所有阶段的活动,包括研究设计、实施和传播。然而,患者合作伙伴参与的类型和程度差异很大。PPI的积极影响包括:(1)研究及研究过程质量的提高;(2)患者合作伙伴权能的增强;(3)研究透明度及结果传播;(4)研究伦理;(5)研究团队与患者群体之间的信任和尊重。在确定的13个障碍中,最常报告的3个是资源不足、让患者合作伙伴充分参与的时间不够,以及关于如何落实“患者合作伙伴”角色的不确定性。在确定的12个促进因素中,最常提到的两个是:(1)有让患者作为研究合作伙伴参与的明确目的;(2)有多个患者合作伙伴参与研究。
PPI对PREFER研究有许多积极影响。有PPI经验的偏好研究负责人报告的积极影响比没有此类经验的人更多。鉴于已确定的众多障碍,应考虑多方面的实施策略,以支持PPI在偏好研究中的采用、整合和持续开展。还需要更多患者合作伙伴参与偏好研究的案例研究,以为该领域的最佳实践提供参考。